Reliability and validity of the Wolfram Unified Rating Scale (WURS)

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Nguyen, Chau ^a   Foster, Erin R ^a   Paciorkowski, Alexander R ^c   Viehoever, Amy ^a   Considine, Colleen ^a   Bondurant, Aidena ^a   Marshall, Bess A ^a   Hershey, Tamara ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BEHAVIOR; BODY EQUILIBRIUM; CLINICAL ARTICLE; CONCURRENT VALIDITY; CONTENT VALIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; MALE; MOOD; MOTOR ACTIVITY; NEURONAL CEROID LIPOFUSCINOSIS; PREDICTION; QUALITY OF LIFE; SCORING SYSTEM; TEST RETEST RELIABILITY; WOLFRAM SYNDROME; WOLFRAM UNIFIED RATING SCALE;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; WOLFRAM SYNDROME; YOUNG ADULT;

EID: 84868676056     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-89     Document Type: Article

References (30)

1. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Barrett TG, Bundey SE, Macleod AF, Lancet 1995 346 8988 1458 1463 10.1016/S0140-6736(95)92473-6 7490992
2. Current developments in wolfram syndrome. Ganie MA, Bhat D, J Pediatr Endocrinol Metab 2009 22 1 3 10 19344068
3. Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Kumar S, Pediatr Diabetes 2010 11 1 28 37 10.1111/j.1399-5448. 2009.00518.x 20015125
4. A clinical rating scale for Batten disease. Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S, et al. Neurology 2005 65 2 275 10.1212/01.wnl.0000169019.41332.8a 16043799 (Pubitemid 41022374)
5. Unified Huntington's disease rating scale: reliability and consistency. Kremer H, Mov Disord 1996 11 2 136 142 8684382
6. Unified Parkinson's disease rating scale characteristics and structure. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez- Sarriés J, Bermejo F, Mov Disord 1994 9 1 76 83 10.1002/mds.870090112 8139608 (Pubitemid 24022618)
7. Quantitative telemedicine ratings in Batten disease. Cialone J, Augustine E, Newhouse N, Vierhile A, Marshall F, Mink J, Neurol 2011 77 20 1808 1811 10.1212/WNL.0b013e3182377e29
8. Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Adams HR, Beck CA, Levy E, Jordan R, Kwon JM, Marshall FJ, et al. Dev Med Child Neurol 2010 52 7 637 643 10.1111/j.1469-8749.2010.03628.x 20187884
9. Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Kwon J, Adams H, Rothberg P, Augustine E, Marshall F, Vierhile A, et al. Neurol 2011 77 20 1801 1807 10.1212/WNL.0b013e318237f649
10. Females experience a more severe disease course in batten disease. Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. J Inherit Metab Dis 2012 35 549 555 10.1007/s10545-011-9421-6 22167274
11. Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data. Cialone J, Augustine EF, Newhouse N, Adams H, Vierhile A, Marshall FJ, et al. J Inherit Metab Dis 2011 34 5 1075 1081 10.1007/s10545-011-9346-0 21556831
12. Effects of Gender and Age on Motor Exam in Typically Developing Children. Gidley Larson JC, Mostofsky SH, Goldberg MC, Cutting LE, Denckla MB, Mahone EM, Dev Neuropsychol 2007 32 1 543 562 2007/07/06 10.1080/87565640701361013 17650993 (Pubitemid 47237392)
13. Revised Neurological Examination for Subtle Signs (1985). Denckla MB, Psychopharmacol Bull 1985 21 4 773 4089106
14. Using psychometric techniques to improve the Balance Evaluation System's Test: the mini-BESTest. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A, J Rehabil Med Offic J UEMS Eur Board Phys Rehabil Med 2010 42 4 323
15. The Child Behavior Checklist and related forms for assessing behavioral/emotional problems and competencies. Achenbach TM, Ruffle TM, Pediatr Rev 2000 21 8 265 10.1542/pir.21-8-265 10922023
16. A measure of anxiety symptoms among children. Spence SH, Behav Ther 1998 36 5 545 566 10.1016/S0005-7967(98)00034-5 (Pubitemid 28288652)
17. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents. Spence SH, Barrett PM, Turner CM, J Anxiety Disord 2003 17 6 605 625 10.1016/S0887-6185(02)00236-0 14624814 (Pubitemid 37414900)
18. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Varni JW, Burwinkle TM, Seid M, Skarr D, Ambul Pediatr 2003 3 6 329 341 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2 14616041 (Pubitemid 37527280)
19. The content validity index: Are you sure you know what's being reported? Critique and recommendations. Polit DF, Beck CT, Res Nurs Health 2006 29 5 489 497 10.1002/nur.20147 16977646 (Pubitemid 44594836)
20. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Polit DF, Beck CT, Owen SV, Res Nurs Health 2007 30 4 459 467 10.1002/nur.20199 17654487
21. Selection and use of content experts for instrument development. Grant JS, Davis LL, Res Nurs Health 1997 20 3 269 274 10.1002/(SICI)1098-240X(199706) 20:3<269::AID-NUR9>3.0.CO;2-G 9179180
22. Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Varni JW, Burwinkle TM, Lane MM, Health Qual Life Outcome 2005 3 34 10.1186/1477-7525-3-34 (Pubitemid 41522154)
23. Guidance for industry: qualification process for drug development tools: draft guidance. FDA, Silver Spring, MD: Center for Drug Evaluation and Research 2010
24. Neuropathy in Wolfram syndrome. Mathis S, Maisonobe T, Neau JP, Eur J Med Genet 2010 54 1 73 75 Jan-Feb 20888932
25. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Chaussenot A, Bannwarth S, Rouzier C, Vialettes B, Mkadem SAE, Chabrol B, et al. Ann Neurol 2011 69 3 501 508 10.1002/ana.22160 21446023
26. The PedsQL™ in type 1 and type 2 diabetes. Varni JW, Burwinkle TM, Jacobs JR, Gottschalk M, Kaufman F, Jones KL, Diabetes Care 2003 26 3 631 637 10.2337/diacare.26.3.631 12610013 (Pubitemid 36929319)
27. The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity. Varni JW, Burwinkle TM, Seid M, Skarr D, Ambul Pediatr 2003 3 6 329 341 10.1367/1539-4409(2003)003<0329:TPAAPP>2. 0.CO;2 14616041 (Pubitemid 37527280)
28. Development and validation of the Diabetes Care Profile. Fitzgerald JT, Davis WK, Connell CM, Hess GE, Funnell MM, Hiss RG, Eval Health Prof 1996 19 2 208 230 10.1177/016327879601900205 10186911 (Pubitemid 26162488)
29. The development of an instrument for assessing the quality of life of people with diabetes: Diabetes-39. Boyer JG, Earp JAL, Med Care 1997 35 5 440 10.1097/00005650-199705000-00003 9140334
30. Early Brain Vulnerability in Wolfram Syndrome. Hershey T, Lugar HM, Shimony JS, Rutlin J, Koller JM, Perantie DC, et al. PLoS One 2012 7 7 40604 10.1371/journal.pone.0040604 22792385